Friday,
December 2, 2016 at 7 PM - 9 PM
First
Unitarian Universalist Society of San Francisco
1187
Franklin St,
San
Francisco, California 94109
Join
Rick Doblin, founder and executive director of the Multidisciplinary
Association for Psychedelic Studies (MAPS) for a conversation about what
inspired him to found MAPS in 1986, the current state of MAPS drug development
plan for MDMA-assisted psychotherapy for PTSD, and the future of
psychedelic-assisted therapy. This presentation will discuss results from the
Phase 2 MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD
studies, and the transition to Phase 3 clinical trials.
Also
discussed will be the ongoing studies for MDMA-assisted psychotherapy for
anxiety associated with a terminal illness, MDMA-assisted psychotherapy for
social anxiety in autistic adults, and medical marijuana for PTSD. The
conversation will conclude with a discussion about regulation of MDMA-assisted
psychotherapy post-approval and what that would mean for therapists, the plan
to build a network of in-patient psychedelic clinic treatment centers, how the
Zendo Project and harm reduction can help us prepare for a post-prohibition
world, and the consequences of the presidential election on our planning.
This
event is an educational program of the CIIS Center for Psychedelic Therapies
and Research in collaboration with CIIS Public Programs & Performances.
Cost:
$15
